June 26, 2018
PHILADELPHIA (Embargoed until 12 p.m. EDT, Tuesday, June 26, 2018) – Research presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates for the first time the benefit of providing earlier lutetium-177 (177Lu) prostate-specific membrane antigen (PSMA) radioligand therapy to patients with metastatic prostate cancer. Until now, this therapy has only been used in patients with end-stage disease.
The study included 224 patients with metastatic prostate cancer, who were restaged following diagnosis with gallium-68 (68Ga)-PSMA positron emission tomography/computed tomography (PET/CT)—the diagnostic partner of 177Lu-PSMA radioligand therapy (PRLT); the two form a theranostic nuclear medicine pairing. Theranostics refers to the combination of a predictive biomarker, in this case PSMA, identified through diagnostic imaging using radiolabeled ligands (which lock onto the specific cancer cell receptor/biomarker), with precise therapy targeted on the now-identified cancer cells. The cancer cells are destroyed, while healthy cells are unharmed—minimizing side effects and improving quality of life for patients.
The patients were grouped according to previous therapies, which included surgery, chemotherapy and external beam radiation therapy. Serum prostate specific antigen (PSA) levels were monitored before and after therapy with 177Lu PRLT.
Study results showed a reduction in PSA level in 70 percent of the patients treated with 177Lu PRLT, and 54 percent had their PSA decline by more than 50 percent. The median overall survival in all patients was 27 months. First-line PRLT was associated with the longest survival (all 18 patients alive at 55 months). Patients previously treated with chemotherapy had a significantly shorter survival (median of 19 months). Survival was also shorter in patients with previous radium-223 (223Ra) treatment (17 months). On the other hand, prior surgical or radiation treatment of the primary tumor had no significant effect on overall survival. Patients demonstrating a PSA decline of more than 50 percent after at least two PRLT cycles, lived significantly longer (38 months). Additional treatment with newer antiandrogen agents Abiraterone or Enzalutamide in combination with 177Lu PRLT also prolonged survival.
“Our study demonstrates a potential survival benefit and superior response after early initiation of 177Lu-PSMA radioligand therapy,” explains Harshad R. Kulkarni, MD, of the THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka in Bad Berka Germany. “PRLT was safe with no or minimal side effects. These results are, therefore, likely to have a significant impact on patients’ lives—maintaining their quality of life for longer.”
He points out, “This approach of precision oncology uses the concept of theranostics—i.e., we see what we treat, and we treat what we see. 177Lu-PRLT patients were selected and followed-up with 68Ga-PSMA PET/CT, using the same ligand for molecular imaging and molecular radiotherapy.”
Kulkarni adds, “These findings will help to determine the right place of 177Lu-PSMA radioligand therapy in the treatment of metastatic prostate cancer—for example before chemotherapy—and serve as a starting point for a prospective randomized controlled clinical trial.”
FIGURE: Persistent complete remission on long-term follow-up after early Lu-177 PSMA radioligand therapy. Lymph node and osseous metastatic, castration-resistant, and chemotherapy-naive prostate cancer (status post androgen-deprivation therapy using LHRH analogs and Bicalutamide) in a 62-year-old patient demonstrated no evidence of disease on Ga-68 PSMA PET/CT 8 months (center) and 17 months (right) after first PRLT. Credit: HR Kulkarni et al., THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany
Abstract 529: “Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer,” Harshad R. Kulkarni, MD; Christiane Schuchardt; Aviral Singh, MD, MSc; Thomas Langbein; and Richard P. Baum, MD, PhD, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany. SNMMI’s 65th Annual Meeting, June 23-26, Philadelphia.
Please visit the SNMMI Media Center for more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. 2018 SNMMI Annual Meeting abstracts can be found online at http://jnm.snmjournals.org/content/59/supplement_1. Current and past issues of The Journal of Nuclear Medicine are online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.